Pharmena mulls switch to WSE main market
21:38
Listed on the small-cap, alternative NewConnect market, biotechnology company Pharmena, plans to transfer its shares to the main WSE market by the end of this year, the company said in a market filing. In H1, the company had PLN 0.5 million net profit, compared with PLN 1.5 million loss last year. Revenues amounted to PLN 6.6 million, up by 7.3 percent y/y.
